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Abstract 
Background: Primaquine is a gametocytocidal drug recommended by the World Health Organization (WHO) in a 
single-low dose combined with artemisinin-based combination therapy (ACT) for the treatment and prevention of 
Plasmodium falciparum malaria transmission. Safety monitoring concerns and the lack of a universal validated and 
approved primaquine pharmacovigilance tool is a challenge for a national rollout in many countries. This study aimed 
to explore the acceptance, reliability and perceived effectiveness of the primaquine roll out monitoring pharmacovigi-
lance tool (PROMPT).
Methods: This study was conducted in three dispensaries in the Coastal region of Eastern Tanzania. The study held 
six in-depth interviews with healthcare providers and six participatory focus group discussions with malaria patients 
(3) and parents/guardians of sick children (3). Participants were purposively sampled. Thematic analysis was con-
ducted with the aid of NVivo qualitative analysis software.
Results: The respondents’ general acceptance and perceived effectiveness of the single-low dose primaquine and 
PROMPT was good. Screening procedure for treatment eligibility and explaining to patients about the possible 
adverse events was considered very useful for safety reasons. Crushing and dissolving of primaquine tablet to get the 
appropriate dose, particularly in children, was reported by all providers to be challenging. Transport costs and poor 
access to the health facility were the main reasons for a patient failing to return to the clinic for a scheduled follow-
up visit. Treatment was perceived to be safe by both providers and patients and reported no case of a severe adverse 
event. Some providers were concerned with the haemoglobin drop observed on day 7.
Conclusion: Single-low dose primaquine was perceived to be safe and acceptable among providers and patients. 
PROMPT demonstrated to be a reliable and user-friendly tool among providers. Further validation of the tool by 
involving the National Malaria Control Programme is pivotal to addressing key challenges and facilitating primaquine 
adoption in the national policy.
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Background
About 3.2  billion people are at risk of malaria despite 
the progressive global decline of malaria prevalence. In 
2019, there were over 200  million new cases of malaria 
and 409,000 deaths; approximately 94% occurred in sub-
Saharan Africa [1]. Malaria is the leading cause of mor-
bidity and mortality in Tanzania, especially in children 
under five and pregnant women. Each year, about 12 mil-
lion people contract malaria in Tanzania and approxi-
mately 80,000 deaths [2].
Global efforts for malaria control, including the use of 
insecticide-treated nets (ITNs), malaria rapid diagnos-
tic test (RDT), indoor residual spraying (IRS), and effec-
tive chemotherapy, have successfully managed to reduce 
malaria by two-fold in the past 15  years [3]. To achieve 
the World Health Organization (WHO) goal of eliminat-
ing malaria by 2035, there is a need to address potential 
challenges facing artemisinin-based combination therapy 
(ACT), particularly with emerging of P. falciparum resist-
ance against artemisinins and their poor gametocytocidal 
effect [4]. The use of effective chemotherapy, such as pri-
maquine with gametocytocidal properties may reduce 
P. falciparum transmission and suppress the spread of 
artemisinin-resistant falciparum malaria [5]. Thus, the 
WHO currently recommends a single low-dose (SLD) of 
primaquine (0.25  mg base/kg) to be administered to all 
patients with parasitological-confirmed P. falciparum 
malaria on the 1st day of treatment in addition to ACT, 
except for pregnant women and infants < 6  months [6]. 
The strategy is likely to be effective in reducing malaria 
transmission in areas of low-intensity malaria transmis-
sion. Testing for glucose-6-phosphate dehydrogenase 
(G6PD) deficiency is not required with the recommended 
low primaquine dose [6].
The main concern about the safety of primaquine is the 
risk for acute haemolytic anaemia (AHA) in G6PD defi-
cient individuals. There is strong evidence that supports 
the safety of SLD primaquine, even in people with G6PD 
deficiency by not causing clinically significant AHA [7–
10]. Despite the latter, many sub-Saharan countries still 
hesitate to include primaquine in their national malaria 
treatment policies due to challenges related to safety 
monitoring [11]. Screening for AHA life-threatening risk 
factors associated with primaquine, such as low haemo-
globin level and previous history of aminoquinoline drug 
reaction may be challenging in routine practice. This 
challenge is even more prominent in remote facilities 
in many developing countries where medical resources 
including, qualified clinicians and supplies are scarce 
[12]. This is a paramount concern considering little is 
known about pharmacovigilance tools that may be use-
ful in a real-world environment and existing uncertain-
ties around practical implementation of the best clinical 
management of haemolytic reaction.
However, the deployment option of SLD primaquine 
is still widely accepted in the treatment of confirmed 
clinical malaria cases, among other interventions [13]. It 
is, therefore, essential for the National Malaria Control 
Programme (NMCP) to have an effective and feasible 
monitoring mechanism in place for evaluating the effec-
tiveness and safety of malaria case management during 
the rollout of SLD primaquine. Having an effective and 
feasible primaquine pharmacovigilance tool may fast 
track resource-limited nations to adopt primaquine in 
their national policy as a treatment of choice for uncom-
plicated P. falciparum.
The Malaria Elimination Initiative (MEI) at the Uni-
versity of California, San Francisco (UCSF) has devel-
oped a comprehensive ‘Primaquine roll out monitoring 
pharmacovigilance tool’ (PROMPT) [14], which serves 
as a healthcare provider guide for monitoring this new 
malaria treatment regimen from day 0 to 7. The tool was 
used to support NMCP policy adoption and roll out of 
SLD primaquine in Eswatini (formerly Swaziland) and 
Senegal [15]. There is a need to validate the tool in East 
African countries, where there is a significant shortage 
of qualified clinicians, scarce medical resources and sup-
plies, a low literacy rate in the community and a relatively 
high G6PD deficiency [16]. Therefore, the PROMPT was 
tested in a real-world environment at the lowest health 
facility delivery level in a rural coastal area in Eastern 
Tanzania to demonstrate its acceptance, reliability, and 
perceived effectiveness among health care providers in 
managing uncomplicated malaria cases with artemether–
lumefantrine (AL) + SLD primaquine.
Methods
Study setting
The study was conducted in Kibiti and Ikwiriri districts 
in the Coastal region, Eastern Tanzania. The two dis-
tricts border each other and have similar geographical, 
economic and population characteristics. The estimated 
total population in the two districts is 248,230 in 94 regis-
tered villages and 385 hamlets. The main economic activ-
ities in the area are small-scale farming, fishing, retailing 
and animal keeping. The districts are part of the hot and 
humid coastal plain with varying tropical climatic condi-
tions. Malaria transmission in the area is hyperendemic, 
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highest during and after the long rain period. Malaria is 
one of the main diseases responsible for most outpatient 
health facility attendance in the district. The two districts 
have two hospitals, five health centres and 48 dispensa-
ries predominantly owned by the government. The study 
area has been described in detail elsewhere [17].
PROMPT trial description
The trial was conducted from March to August 2020. 
Prior to the onset of the trial, a situation health facility 
survey was conducted in three sampled government-
owned dispensaries. Stratified random sampling was 
used to select study facilities. Firstly, government-owned 
dispensaries were identified in villages with no malaria 
control research interventions and stratified by district. 
Simple random sampling technique was used to select 
one out of 4 dispensaries in Kibiti and two dispensaries 
out of 5 in Rufiji district. The survey aimed to deter-
mine facilities’ readiness in screening and managing 
primaquine related adverse events. The survey focused 
on the following using a checklist; (i) human resource 
capacity in terms of number and qualification of health 
care providers, (ii) laboratory capacity in terms of avail-
able resources necessary for malaria and anaemia screen-
ing, (iii) essential supplies for managing severe acute 
haemolytic anaemia, and (iv) facility system and means 
in place for referring patients with emergence condi-
tions. Facilities were then capacitated to manage malaria 
patients with uncomplicated P. falciparum malaria using 
SLD primaquine plus AL based on the findings from the 
needs assessment survey. Facility capacitation including 
familiarizing providers with PROMPT through training, 
pilot and adapting the tool. Facilities were being supplied 
with enough anti-malarials, ORS,  haemoCue® machine, 
weighing machine, stationary, Hillmen urine colour 
chart, and laboratory consumables necessary to manage 
and follow a patient treated with primaquine. Further-
more, PROMPT package documents, including patient 
data collection form and patient information card, were 
also supplied throughout the trial period. None of the 
research team members was present in the facilities dur-
ing the trial period to support recruitment, screening, 
prescription, patient follow-up or site supervision. This 
was important to ensure the trial is implemented in a 
routine healthcare environment by the existing facility 
personnel and system without any external interference.
A tablet of 7.5 mg primaquine (Sanofi-Aventis Cyprus 
Limited) was used. A single dose of primaquine using 
PROMPT defined therapeutic dose range that is equiva-
lent to 0.25 mg/kg primaquine base was administered; 0.5 
tablet to 10–15 kg patient, 1 tablet to 16–30 kg patient, 
1.5 tablets to 31–45  kg patient, and 2 tablets to patient 
above 45  kg [14]. A 7.5  mg base primaquine phosphate 
tablet was crushed and dissolved in 7.5  ml of drinking 
water to produce a stable  1  mg/ml solution. A sterile 
syringe was used to draw the assigned dose to the near-
est 0.5  ml and immediately gave it to the participant in 
a spoon to swallow together with the sweet beverage, 
mainly soda and fruit punch. The approach has been 
described elsewhere [18]. Primaquine was administered 
under direct observation at the facility together with the 
first doses of AL  (Coartem®, Novartis; artemether 20 mg 
and lumefantrine 120 mg). Patients were not screened for 
G6PD deficiency.
Study design
This study employed a qualitative cross-sectional design 
involving in-depth interviews (IDIs) and focus group dis-
cussions (FGDs). The study was conducted in July 2020, 
when the trial was in its 5th month of implementation.
Sampling
Purposive sampling was performed to achieve uniform 
representation of the three main FGDs of eligible patients 
participated in the trial including male, female, and par-
ents or guardian with sick children. Since each study 
facility had only one clinician and two to three nurses, all 
clinicians and nurses who spend most of their time in the 
outpatient unit were selected to participate in the IDIs in 
each facility. All the study facilities did not have a labora-
tory or pharmacist attendant.
Data collection
A total of six (three clinicians, three nurses) IDIs was 
conducted with the healthcare providers (HCP) from 
all three facilities. IDIs collected information on pro-
vider’s perceptions and experience in patient screen-
ing, PROMPT data collection form, PROMPT patient 
information card, primaquine prescription and dosage, 
patient follow-up, and treatment safety concerns. Six 
FGDs were conducted with patients (with 24 males and 
27 females) treated with SLD primaquine involving three 
groups; adult men, adult women, and parents or guard-
ians with malaria-treated young children. The breakdown 
for the six FGDs is: 2 with males, 2 with females, and 2 
with parents/guardians with sick children. Each FGD 
had 8 to 9 participants and explored patients’ percep-
tion of overall management experience from providers, 
day 7 follow-up, treatment safety concern, and outcome. 
The IDI and FGDs were conducted using a topic guide 
that had been pilot-tested. Two experienced qualitative 
researchers conducted IDIs and FGDs in Swahili and in 
a private place to ensure confidentiality. All the IDIs and 
FGDs were audio recorded and transcribed verbatim and 
later translated into English.
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Data analysis
Thematic analysis was done with the aid of NVIVO quali-
tative analysis software. Transcripts were imported into 
NVivo, and coding was done by two researchers involved 
in the data collection. Transcripts were initially read 
and a priori and emerging codes were developed. Two 
researchers, including the first author, examined the 
coded data and developed it into themes. Hypotheses 
were generated through repeated reading of themes.
Ethical considerations
This study was conducted in accordance with the Decla-
ration of Helsinki, ICH Good Clinical Practice, and local 
regulatory requirements from the Tanzania Medicines 
and Medical Devices Authority (TMDA). The study is 
registered with the Pan African Clinical Trial Registry 
(Number PACTR202007653561223). Ethical approval 
was granted by the Ifakara Health Institute (IHI) ethical 
review board and the Tanzania National Research Ethics 
Committee (Number NIMR/HQ/R.8a/Vol.IX/3114). Vol-
untary written informed consent was obtained from all 
study participants. Confidentiality of the data obtained 
from participants was strictly secured and maintained.
Results
The median age of study participants was 35 (rang-
ing from 27 to 46) years. Providers had on average, had 
6  years of experience providing health care and had 
worked in the study area for at least 3 years. Among the 
three clinicians, two were males and one female. All cli-
nicians had the academic qualification level of medi-
cal assistants, referred to as clinical officers in Tanzania. 
All the nurses were females with the professional title of 
Enrolled Nurses. At the time of the interview, each facil-
ity had already treated at least 150 patients with SLD pri-
maquine co-administered with AL.
The age of the FGD participants ranged from 19 to 
44 years, and their education level ranged from no school 
to ordinary secondary school level. All participants were 
residents of the study area and had a prior experience 
being treated for malaria with AL only.
Patient screening experience
All participating HCP supported the importance of 
screening patients for the recommended treatment eli-
gibility criteria, starting with a detailed patient medi-
cal history and conducting a physical examination and 
laboratory tests. This is also part of their medical train-
ing to screen all patients before treatment and not only 
for suspected malaria cases. More than two-thirds of the 
providers mentioned that screening patients for SLD pri-
maquine as outlined in the PROMPT is clear to follow 
and guides them better towards the appropriate man-
agement, particularly to some criteria that can easily be 
overlooked and missed.
“The screening information in the guide helps me to 
make sure I have assessed all patient’s eligibility cri-
teria for this new malaria treatment otherwise, you 
can easily miss important medical conditions such 
as an allergy to other malaria drugs or even preg-
nancy”. IDI, Nurse aged 46
“Routine screening for anaemia has helped us a lot 
to diagnosed malaria patients with severe anaemia 
because previously, we did not often measure Hb 
when we see a child is stable. Now we are surprised 
to see a child with Hb below 4 g/dl and is stable and 
walking”. IDI, Clinical Officer aged 35
HCP mentioned some challenges regarding patient 
screening. About half of the providers said that they 
spend more time attending to a patient because of going 
through the eligibility criteria and screening for anaemia 
even though they were using a rapid anaemia screening 
machine  (HemoCue® machine). Some providers were 
also concerned about the sustainability of routine screen-
ing for anaemia because of limited supplies to support 
such an exercise beyond the programme funding period.
One provider mentioned that the workload at public 
health was already too much:
“Explaining to the patient about this new treat-
ment and anaemia screening to all before treatment 
is somehow demanding in our facility because I am 
the only clinician here together with two nurses who 
spend most of the time in reproductive and child 
health (RCH) clinic and labour room, and no labo-
ratory officer…., so you can imagine the workload I 
have, measuring Hb to all patients receiving pri-
maquine and at the same time managing other cases 
as well as facility administrative duties”. IDI, Clini-
cal Officer aged 35
In reference to the stockout challenge, one provider 
expressed her scepticism in the following:
“…… I’m not sure about how this be sustained con-
sidering the stock out of supplies, particularly the 
trips used in the Hemocue machine for measuring 
Hb is a chronic problem in our district. A facility 
may take up to two months or more without meas-
uring Hb, forcing us to refer patients to other facili-
ties only to check Hb”. IDI, Nurse aged 34
The majority of the patients mentioned the providers 
took more time exploring their medical history when 
comparing with their previous experience in the same 
facility. They felt more valued by the clinician by showing 
Page 5 of 10Mosha et al. Malar J          (2021) 20:392  
more concern about the presenting illness and even tak-
ing blood for anaemia screening whenever they are found 
to have malaria.
“…… in the past, doctors appeared to be rushing in 
order to clear the number of patients waiting for his 
service … he may just ask you few questions about 
how you feel and immediately tells you to go and 
check for malaria. At times you even hesitate to ask 
him all your questions, assuming that you might 
waste his time….. This time is different; he asks you 
different questions and even wants to know whether 
you are pregnant while you just came for malaria 
treatment”. FGD, female patients
Patient treatment information
HCP provided the information on primaquine treat-
ment and possible adverse events, including assessing 
their urine colour changes at home, having the Hillmen 
Urine Colour Chart for reference. They were also insisted 
on returning to the clinic on day 7 to follow up with all 
patients. They also reported having given all patients a 
PROMPT patient information card, a sheet of paper with 
about 70 words that mention the treatment received, 
possible primaquine side effects, the date for day 7 follow 
visit and the provider’s cellphone number. Nearly all pro-
viders mentioned patients are happy with the informa-
tion card provided, especially by including the provider’s 
phone number.
"Patients are happy with the sheet we are providing 
to them because it has our phone numbers so as they 
can call and ask questions when they are at home 
or even sometimes when the facility is closed”. IDI, 
Clinical Officer aged 38
HCP reported that they frequently received regular 
calls from patients and responded to their questions, 
including matters unrelated to malaria.
“Our phone numbers provided in the card makes 
it easier for the patients to reach us whenever they 
see something is wrong with them….. I remember the 
last call came from a patient complaining of hav-
ing dark urine, and I told him to come back imme-
diately in the morning for a checkup”. IDI, Clinical 
Officer aged 35
Patients are happy with the information card because 
apart from the providers’ phone number provided, they 
also mentioned that the information card reminds them 
of the adverse events related to the primaquine use. How-
ever, the information card was not as useful to illiterate 
patients, and most depended on literate family members 
to read for them.
I was provided with a sheet explaining the treat-
ment, which I think is something good, but I couldn’t 
read it, and no one at home could help me”. FGD, 
female patients
Many patients also attested to the good service from 
the HCP. They reported that the information provided 
was clear and useful even for those who could not read 
or write.
“…… as you can see most of us can’t read this infor-
mation sheet at home due to different reasons but 
I think the information explained by the doctor 
in the facility was clear and the good thing in this 
sheet there is doctor’s phone number, and she said to 
call her at any time when we see something is going 
wrong”. FGD, male patients
HCPs also mentioned that despite being aware of most 
of their patients being illiterate, they still provided infor-
mation cards to all treated patients as per the PROMPT 
protocol.
“Many people in our community don’t know how to 
read and write, but we still give them the form and 
advise to ask someone at home to read for them for 
more understanding”. HCP in IDI 03
Contrary to the broader positive view regarding pro-
viding treatment information to the patients as indicated 
in the PROMPT, there were other opinions whereby 
providers found it challenging. They feel some patients 
do not understand the message clearly when explaining 
to them in the clinic. Some take mixed messages to the 
community about the treatment leading to misperception 
of the treatment.
“Level of understanding of patients is very low. Some 
don’t understand and at some point, they send dif-
ferent message messages to the community about 
primaquine prescribed”. IDI, Nurse aged 34
Nearly half of the providers mentioned limited time to 
explain to each patient clearly about the treatment and 
responding to patients queries as a key challenge.
“Sometimes it is hard to explain in detail every-
thing to the patient about primaquine due to a big 
number of patients who are waiting to be attended, 
and some are in critical condition hence, forces us to 
summarize the information on the key safety issues”. 
IDI, Clinical Officer aged 32
Primaquine prescription and administration
All the providers mentioned the primaquine dosage chart 
from PROMPT defined therapeutic dose range and this 
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is constructive as it guides them to choose the appro-
priate dose based on the patient’s weight. The challenge 
mentioned was when there is a need to crush a tablet and 
come with the proper amount, particularly for patients 
with the age range of 10–15 kg (require 0.5 tablet of pri-
maquine 7.5  mg) and 31–24  kg (require 1.5 tablets of 
primaquine 7.5 mg). All providers talked about the chal-
lenge related to the administration of primaquine by dis-
solving first the tablet of 7.5 mg in a small glass tube with 
7.5 ml clean water. After that, draw with a syringe to get 
the required patient dose as instructed in study training 
for treating malaria with SLD + ACT. Nearly all providers 
were also concerned about the bitter taste of dissolved 
primaquine and thus were administering it to the patient 
together with a sweet beverage to mask the bitterness. 
This was thought to subject a patient to unnecessary cost 
in the absence of support from the study. All the provid-
ers recommended the need to have a new primaquine 
formulation that requires no crushing or dissolving the 
tablet.
“It is very challenging for us to dissolve first the tab-
let in water to estimate the recommended patient 
dose. This is something that is new to us and very 
difficult in the actual practice of our environment….. 
we think it is an unnecessary additional cost to the 
patient by taking soda together with dissolved pri-
maquine tablet so as not to feel the bitterness”. IDI, 
Nurse aged 34
“….good to have dose-specific tablets for patients 
according to their age and weight like other treat-
ment and not to crush the tablet that is very small 
than piriton (chlorphenamine tablet which is con-
sidered to be the smallest tablet by many providers)”. 
IDI, Nurse aged 27
However, patients including parents and guardians 
with young children, mentioned that it was not a prob-
lem taking a tablet dissolved in water. The sweet beverage 
provided for swallowing primaquine made the experience 
of swallowing the medicine desirable among children.
“The medicine was ok and my child was fine with 
the taste, I think it was because of the soda used to 
diluting the medicine… sometimes at home, they are 
asking if we can go again to the hospital and take the 
malaria medicine”. FGD, parents/guardian
Patient follow‑up experience
Most of the patients supported the importance of follow 
up in the facility after treatment to ensure that they were 
progressing in good health. However, they were con-
cerned about the transportation challenges when coming 
to the facility for the scheduled follow up visit. Reflecting 
on access barriers and transport costs for a return visit, a 
patient reported:
“The challenge of coming back on day seven after a 
treatment has transportation challenges to some of 
us who are staying far from this facility… we use a 
lot of money in the commuter bus and bodaboda 
(motorbike taxi) to reach to this facility”. FGD, 
female patients
A second patient talked about access in the following:
“Many of us are staying far from the facility and the 
road is poorly accessible especially during the rainy 
season that’s why some of our friends failed to come 
back… but I assure you if you want all of us to come 
back as scheduled, then you should consider reim-
bursing our transportation expenses”. FGD, male 
patients
All HCP supported the importance of patients return-
ing on day 7 for the follow-up. Determining the haemo-
globin status post-treatment was the main reason for 
the latter. A big drop in haemoglobin level was observed 
among most patients, albeit no one mentioned the inci-
dence of significant haemoglobin drop, leading to severe 
anaemia.
“….this is very important to follow patients so as to 
be sure of their Hb (haemoglobin) status after treat-
ment because of what we observed… I can say most 
patients presented with Hb drop of about 1 to 3 
units from the original value”. IDI, Clinical Officer 
aged 38
HCPs were also concerned with patients transportation 
challenges, responsible to some patients failing to return 
to the clinic for follow up. Failure to return was perceived 
to be attributed to patient behaviour. When the patient 
felt better after completing the medication, they were 
least motivated to see a clinician:
“Some patients don’t come on day 7 as scheduled 
and instead may come on day 10 or not at all simply 
because of transportation challenges to access the 
health facility which is contributed by long distance 
to the facility and poor road condition, having mud 
and flood”. IDI, Clinical Officer aged 32
Data collection form
More than two-thirds of the providers found the 
PROMPT data collection form useful as it helped them 
ensure that they had noted down all the necessary infor-
mation required in making a treatment decision. They 
were not used to only one person completing a similar 
form in a specific fixed order. They mentioned the latter 
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as one of the reasons for a prolonged time in attending to 
malaria patients. They suggested that the form should be 
shortened and that this should be incorporated with the 
existing medical information system.
“We are not used to documenting patients informa-
tion in detail, covering all issues about the treatment 
by following a specific order, step by step, and then 
provide our phone numbers to all patients attended. 
Initially, it was a big burden in terms of time to 
make sure we are not making mistakes, but as time 
goes on, we improved the speed and accuracy” [IDI, 
Nurse aged 34]
Perceived primaquine safety and outcome
All HCP reported no cases of severe adverse events such 
as death, severe anaemia or case referred for blood trans-
fusion or any reason for using SLD primaquine in the 
management of uncomplicated malaria. The treatment 
safety concern mentioned by nearly all providers was the 
drop of haemoglobin level in many patients observed on 
day 7 of follow up but not to the level that may require 
a blood transfusion. Two providers each mentioned to 
have seen the patient coming back complaining of dark 
urine, and after 2 days, the urine was clear. HCPs men-
tioned managing this condition by prescribing oral rehy-
dration therapy (ORS) and was used at home for 2 days. 
None of the providers received a patient with serious 
complaints linked to primaquine, such as stomachache, 
nausea or vomiting.
“I only have experience of one patient presented with 
dark urine after using the treatment, we told him 
to come back on the following day and confirmed 
his urine was dark, but we did not check his Hb 
because day 0 Hb was around 12 points and some-
thing (12 mg/dl). We then gave him 4 sachets of ORS 
(for 4  l) and encouraged him to use them at home; 
after two days, he called us again and was happily 
informing us he is doing ok”. IDI, Nurse aged 46
Nearly half of the providers mentioned the treatment 
has helped reduce the turn-up of patients to the facil-
ity due to recurrence of malaria. This was observed 
since they started including SLD primaquine in treating 
patients with ACT.
“The treatment has reduced a big number of patients 
returning to our facility with malaria in a few days 
after completing malaria treatment. Now it can take 
several months for patients to return to the facility 
for malaria treatment… I can say this new medicine 
has also reduced the number of malaria attended 
cases”. [IDI, Clinical Officer aged 35]
A similar experience was also mentioned in one FGD 
with parents and guardians:
… every month, my children were suffering from 
malaria, but since they started getting this treat-
ment, at least a month has now passed without hav-
ing malaria in my family”. FGD, parents/guardian.
Discussion
The study has shown that a single-low dose primaquine 
regimen and pharmacovigilance monitoring tool among 
healthcare providers and patients in a real-world envi-
ronment is feasible and acceptable. Although some pro-
viders considered it time-consuming, patient screening 
procedures and treatment information were perceived 
to be good and clear to both providers and patients. Pri-
maquine administration had practical challenges in some 
patients who needed to crush and dissolve first the tab-
let to get an appropriate dose. According to the schedule, 
returning to the clinic for treatment follow-up on day 7 
was challenging for patients due to varied reasons.
The treatment was generally perceived as safe by both 
patients and providers with no reported severe adverse 
events. Providers were concerned about the haemoglobin 
level drop observed on the scheduled follow-up visit on 
day 7. Screening for the treatment eligibility criteria as 
per the PROMPT that includes assessment of the specific 
patient safety condition through medical history, clini-
cal and laboratory investigations assisted the clinician 
in identifying life-threatening conditions, particularly 
severe anaemia. Routine laboratory screening for haemo-
globin level is often ignored in patients diagnosed with 
malaria in many low-income countries, reportedly due to 
resources constraints [19]. This may suggest the need to 
use other cheap alternatives for assessing anaemia, such 
as the WHO Haemoglobin colour card in order to sustain 
anaemia screening. However, the WHO Haemoglobin 
colour card is subjected to errors [20]. The present study 
demonstrated the acceptance of providers to screen all 
patients for anaemia before treatment. Children with 
pre-existing anaemia are at risk of severe adverse out-
comes when co-infected with malaria or as a secondary 
consequence to acute haemolytic anaemia, risk in those 
patients with G6PD deficiency [21]. In another paper to 
be submitted shows that under-five children included in 
the study had a mean haemoglobin of 10.3  g/dl. Using 
the PROMPT, patients with haemoglobin below 7  g/dl 
were excluded from receiving SLD primaquine. This may 
explain why no severe adverse event was reported during 
the trial period, considering the prevalence of anaemia 
among children in the study area is above 40% [22].
No study facility could examine blood slides to deter-
mine parasitaemia level or type of malaria parasite 
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because they had no laboratory technician. Therefore, 
malaria diagnosis in the present study was based on RDT, 
the test that is considered more reliable and saves time in 
resource-limited countries, countries mostly challenged 
by having unskilled personnel [23]. The current study 
design did not screen for G6PD or urine colour before 
treatment as they are not primary screening require-
ments in the PROMPT. However, none of the providers 
perceived the two screening tests during the baseline 
would affect the treatment outcome.
Good providers patients interaction, including under-
standing patient’s medical condition, provides the patient 
with relevant detailed information about the treatment, 
and importance for patients to return to the clinic for 
follow-up, as emphasized in the PROMPT, have been 
reported to improve the quality of care and adherence 
to treatment [24]. Patients in the present study were 
happy to see providers take extra time explaining to 
them about the treatment, which is different from their 
previous experience. The patient–provider relationship 
should therefore be promoted to ensure better treatment 
outcomes.
The limited number of health providers in many 
resource-limited countries, including Tanzania, are over-
whelmed with many patients in the clinic. This has been 
reported to affect the quality of care in these countries 
[25]. Time constraints to provide enough information to 
patients about primaquine besides performing all treat-
ment screening procedures was reported to be a big bur-
den by nearly all providers in the study. With the new 
malaria treatment regimen, advocacy to the community 
about the treatment should be emphasized to improve 
the client’s knowledge in advance before attending the 
facility for medical attention. This may reduce the time 
needed for the provider to explain about the treatment. 
Promoting advocacy to the community and opening new 
treatment dialogue has been demonstrated to minimize 
mixed messages about the treatment and improve treat-
ment uptake and adherence [26].
Most patients appreciated the PROMPT patient infor-
mation sheet provided by healthcare providers on the 
first day of treatment, though some could not read and 
write. The latter should not ignore the value of supple-
ment information material to patients because multiple 
information channels have reported improving under-
standing and knowledge of a particular subject matter 
[27]. Disclosing the phone number of a provider in the 
PROMPT patient information sheet aimed to facilitate 
patient-provider communication, mainly when a patient 
is far from the facility and needs immediate medical 
attention or advice. This should be encouraged consider-
ing optimal patient–provider communication has been 
reported elsewhere in the outpatient clinic setting to be 
critical for safety and effective patient care [28]. How-
ever, phone calls from patients were considered a burden 
and irrelevant to some providers because they were not 
related to the treatment. This can be addressed by always 
encouraging patients not to call providers for non-medi-
cal reasons.
PROMPT defined therapeutic dose range is a novel 
idea from MEI research work that aims to simplify pri-
maquine dosing regimen and minimize errors that may 
affect drug safety and efficacy to the patients [14]. Most 
providers reported the usefulness and simplicity of the 
therapeutic dose range guide in determining a patient’s 
dose. A simplified dosing chart for treating a patient has 
been reported to reduce human errors [29]. Therefore, 
there is a need to encourage using the PROMPT defined 
therapeutic dose range guide in treating malaria with 
SLD primaquine, especially in the resource-limited coun-
tries where over-the-counter prescription among non-
medical personnel is common [30, 31].
Administration of primaquine was reported to be chal-
lenging by all providers, particularly where there is a 
need to crush the tablet first in order to get the appropri-
ate dose based on the patient’s body weight. This is due 
to a small tablet size of around 6 mm in diameter, making 
it almost impossible to split it evenly. Unfortunately, the 
lack of the WHO prequalification primaquine tablet with 
lower strength has been reported to be a challenge by 
manufacturers due to limitations related to formulation 
processes [13]. A possible way forward for considera-
tion is to develop a dose band with commonly used ACT. 
SANOFI is currently working on developing accessible 
primaquine dispersible tablets for children [32]. Allow-
ing providers to continue administering SLD primaquine 
by first crushing and dissolving the tablet, particularly in 
the paediatric population, may increase the likelihood of 
administering a wrong dose, as demonstrated elsewhere 
[33]. The bitter taste of a dissolved primaquine tablet 
may also discourage the patient from taking it. A good 
acceptance observed among children to take a crushed 
primaquine tablet may be explained by mixing it with a 
sweet beverage.
Several studies have shown follow-up on patients after 
or through the treatment process to improve patient sat-
isfaction, medical safety and ensure the health-related 
quality of life [34, 35]. Most patients also reported the 
importance of returning to the clinic for medical follow-
up and screened for haemoglobin levels regardless of 
their perceived good clinical progress. This should be 
encouraged when rolling out SLD primaquine because 
it helps to detect any drug-related adverse events, par-
ticularly acute haemolytic anaemia [14]. However, poor 
access to the health facility and transport costs were 
reported by patients to be the key factors responsible for 
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failing to return for the scheduled follow-up visit. Trans-
port cost has also been reported to be the main challenge 
of patients lost to follow-up for their routine treatment 
and care in other sub-Saharan African countries [36, 37]. 
Therefore, there is a need to explore interventions that 
will facilitate patients to turn up to their scheduled fol-
low-up visits. Interventions such as making phone calls 
or sending reminder phone messages may be effective 
considering mobile phone coverage is good in many sub-
Saharan Africa countries [38]. Sending reminders has 
proved to improve the likelihood of the patient keeping 
the medical appointment [39].
There was no severe adverse outcome observed or 
reported by either providers or patients. This agrees 
with the rich available information about the safety of 
SLD primaquine in treating P. falciparum malaria [7–9]. 
Providers were mainly concerned with the haemoglo-
bin level drop observed at day 7 of follow-up compared 
with the baseline haemoglobin level. A few days after 
malaria treatment, the haemoglobin level drop could be 
mainly due to haemolysis of parasitized red blood cells 
regardless of the patient’s G6PD status [40]. Whether the 
observed day 7 haemoglobin drop was significantly asso-
ciated with the G6PD status of patients will be presented 
separately in the quantitative paper.
Conclusion
This study provided findings on acceptability and the 
safety monitoring of SLD primaquine in routine health-
care practice in rural and the lowest level of health facility 
delivery in low-income countries. Acceptance of the SLD 
primaquine and the use of PROMPT among healthcare 
providers in managing malaria is encouraging. The chal-
lenges observed in the present study calls upon the need 
to validate and customize the primaquine safety monitor-
ing tool to a local context by working with the national 
malaria control programme before SLD roll-out.
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